SavedAdd your journal

Journals / Türk Biyokimya Dergisi / 2020 / Cilt: 45 - Sayı: 6

New pathway in rheumatic mitral valve disease: cytochrome P450 and glutathione S transferase isozyme expression

Romatizmal Mitral Kapak Hastalığında Yeni Yolak: Sitokrom P450 ve Glutatyon S Transferaz İzozim Ekspresyonu

Sadi KAPLAN
Ali Cemal DÜZGÜN
Pınar KAYGIN
Gülçin ŞİMŞEK
Serpil OĞUZTÜZÜN
Erdal ŞİMŞEK
Mehmet Fazıl Tolga SAYOL
Sezen SARIALTIN
Pages
869–876
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

A strategythat would help prevent oxidative stress in patientswith rheumatic mitral valve disease can be a so valuablemeans to affect disease progression.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Cytochrome P450 (CYP)1A1, glutathioneS-transferase pi (GSTP1) and omega (GSTO1) isozymeswere evaluated and compared in patients with the diagnosisof rheumatic mitral valve disease and ischemicmitral valve insufficiency to find out the relationship ofthe oxidativestress with rheumatic mitral valve disease.Materials and methods: The control group consisted ofpatients operated on due to ischemic mitral valve insufficiency(group I, n:14) while study group consisted ofthe patients operated on with the diagnosis of rheumaticmitral valve disease (group II, n:29).
📊
Key Findings & Data:CYP1A1, GSTP1,and GSTO1 immunohistochemical markers were studied.Results: 20.7% of GSTP1 isozyme protein expression wasseen in the study group; however, no expression wasdetected in the control group.
💡
Conclusion & Impact:A strategythat would help prevent oxidative stress in patientswith rheumatic mitral valve disease can be a so valuablemeans to affect disease progression.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Cytochrome P450 (CYP)1A1, glutathioneS-transferase pi (GSTP1) and omega (GSTO1) isozymeswere evaluated and compared in patients with the diagnosisof rheumatic mitral valve disease and ischemicmitral valve insufficiency to find out the relationship ofthe oxidativestress with rheumatic mitral valve disease.Materials and methods: The control group consisted ofpatients operated on due to ischemic mitral valve insufficiency(group I, n:14) while study group consisted ofthe patients operated on with the diagnosis of rheumaticmitral valve disease (group II, n:29). Mitral valve materialswere stained with hematoxylin and eosin. CYP1A1, GSTP1,and GSTO1 immunohistochemical markers were studied.Results: 20.7% of GSTP1 isozyme protein expression wasseen in the study group; however, no expression wasdetected in the control group. This finding was statisticallysignificant in terms of GSTP1 isozyme. No statisticallysignificant differences in the level of GSTO1 andCYP1A1 protein expression between the study and controlgroups were observed.Conclusion: In this study, we found out that GSTP1 isozymemay be related to rheumatic mitral valve disease. A strategythat would help prevent oxidative stress in patientswith rheumatic mitral valve disease can be a so valuablemeans to affect disease progression.

Özet

Amaç: Romatizmal mitral kapak hastalığı ve iskemik mitral kapak yetmezlikli hastalarda Sitokrom P450 (CYP)1A1, glutatyon S-transferaz pi (GSTP1) ve omega (GSTO1) izozimleri karşılaştırılarak, romatizmal mitral kapak hastalığı ile oksidatif stres arasındaki ilişki araştırıldı. Gereç ve Yöntem: Kontrol grubunu, iskemik mitral kapak yetmezliği sebebiyle ameliyat edilen (group I, n:14), çalışma grubunu ise romatizmal mitral kapak hastalığı nedeni ile ameliyat edilen (group II, n:29) hastalar oluşturmuştur. Mitral kapak materyalleri hematoksilen ve eozinle boyandı. CYP1A1, GSTP1, ve GSTO1 immünohistokimyasal belirteçler ile çalışıldı. Bulgular: Çalışma grubunda %20.7 GSTP1 isozim protein ekspresyonu gözlendi; fakat kontrol grubunda ekspresyon izlenmedi. Bu bulgu GSTP1 izozim açısından istatistiksel olarak önemli bulundu. Çalışma ve kontrol grupları arasında GSTO1 ve CYP1A1 protein ekspresyonları açısından istatistiksel anlamlı farklılık görülmedi. Sonuç: Bu çalışmada GSTP1 izozimi romatizmal mitral kapak hastalığı ile ilişkili olabileceği görüldü. Romatizmal mitral kapak hastalığı olan hastalarda oksidatif stresi önleyen strateji, hastalığın ilerleyişini engellemek için çok değerli bir seçim olabilir.

🔖

Cite This Article

KAPLAN, S., DÜZGÜN, A. C., KAYGIN, P., ŞİMŞEK, G., OĞUZTÜZÜN, S., ŞİMŞEK, E., SAYOL, M. F. T., SARIALTIN, S. (2022). New pathway in rheumatic mitral valve disease: cytochrome P450 and glutathione S transferase isozyme expression. Türk Biyokimya Dergisi, Cilt: 45 - Sayı: 6, 869–876. https://ajindex.com/articles/620820

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Cheitlin MD, Zipes DP. Cardiovascular disease in the elderly. In: Braunwald E, editor. Heart disease a textbook of cardiovascular medicine, 6th ed. Philadelphia: W.B. Saunders Company, 2001:2019–37
  2. Kutay V, Sareyyupoglu B, Kirali K, Yakut C. Effects of high altitude on pulmonary hypertension and surgical morbidity in patients who have rheumatic mitral valve stenosis. Turk Gogus Kalp Damar Cer Derg 2002;10:222–5
  3. Cem Heper, editor. Kardiyoloji. Ankara: Nobel and Gunes press, 2002:365–8
  4. Roberts WC, Perloff JK. Mitral valvular disease: a clinicopathologic survey of the conditions causing the mitral valve to function abnormally. Ann Intern Med 1972;77:939–75
  5. Edwards JE, Rusted IE, Scheifley CH. Studies of the mitral valve, II: certain anatomic features of the mitral valve and associated structures in mitral stenosis. Circulation 1956;14:398–406
  6. Mustafa Pac. Editor, Kalp ve Damar Cerrahisi Edinsel Mitral Kapak Hastalıkları: 2004:487–8, 507–8
  7. Olesen KH. The natural history of 271 patients with mitral stenosis under medical treatment. Br Heart J 1962;24:349–57
  8. Bengel FM, Permanetter B, Ungerer M, Nekolla S, Schwaiger M. Non-invasive estimation of myocardial efficiency using positron emission tomography and carbon-11 acetate–comparison between the normal and failing human heart. Eur J Nucl Med 2000;27:319–26
  9. Wu YW, Naya M, Tsukamoto T, Komatsu H, Morita K, Yoshinaga K, et al. Heterogeneous reduction of myocardial oxidative metabolism in patients with ischemic and dilated cardiomyopathy using C-11 acetate PET. Circ J 2008;72:786–92
  10. Sugiki T, Naya M, Manabe O, Wakasa S, Kubota S, Chiba S, et al. Effects of surgical ventricular reconstruction and mitral complex reconstruction on cardiac oxidative metabolism and efficiency in nonischemic and ischemic dilated cardiomyopathy. JACC Cardiovasc Imaging 2011;4:762–70
  11. Rabus M, Demirbağ R, Sezen Y, Konukoğlu O, Yildiz A, Erel O, et al. Plasma and tissue oxidative stress index in patients with rheumatic and degenerative heart valve disease. Turk Kardiyol Dern Ars 2008;36:536–40
  12. Chopra P, Gulwani H. Pathology and pathogenesis of rheumatic heart disease. Indian J Pathol Microbiol 2007;50:685–97
  13. McCormick ML, Gavrila D, Weintraub NL. Role of oxidative stress in the pathogenesis of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2007;27:461–9
  14. Satriano JA, Shuldiner M, Hora K, Xing Y, Shan Z, Schlondorff D. Oxygen radicals as second messengers for expression of th